EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC TEST FROM MYRIAD GENETICS

Group 1 - Eurobio Scientific has completed the acquisition of the EndoPredict® genomic test from Myriad Genetics, finalizing the agreement initially announced on May 7, 2024 [1] - The acquisition includes the license to distribute the Prolaris® genomic test for prostate cancer, with combined annual revenues from these activities estimated at approximately €8 million [1] - The EBITDA levels from these new activities are expected to dilute the Group's performance in the short and medium term [1] Group 2 - Eurobio Scientific is a prominent player in specialty in vitro diagnostics, involved in research, manufacturing, and commercialization of diagnostic tests across various fields [2] - The company has a workforce of around 290 employees and operates four production units in France, Germany, the Netherlands, and the United States, along with several affiliates in various European countries [2] - Eurobio Scientific is publicly listed on the Euronext Growth market in Paris and is part of several indices, including Euronext European Rising Tech [3]